Heads up!
We’ve moved some things around. Take a quick tour to learn what has changed.
Take the tour
No thanks!
Articaine
Identification
- Name
- Articaine
- Accession Number
- DB09009
- Description
Articaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Articaine (DB09009)
- Weight
- Average: 284.374
Monoisotopic: 284.119463206 - Chemical Formula
- C13H20N2O3S
- Synonyms
- Articaína
- Articaine
- Articainum
- External IDs
- HOE 045
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAcarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Articaine. Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Articaine. Albiglutide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Articaine. Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Articaine. Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Articaine. Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Articaine. Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Articaine. Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Articaine. Disopyramide The therapeutic efficacy of Disopyramide can be decreased when used in combination with Articaine. Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Articaine. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- No interactions found.
Products
- Product Ingredients
Ingredient UNII CAS InChI Key Articaine hydrochloride QS9014Q792 23964-57-0 GDWDBGSWGNEMGJ-UHFFFAOYSA-N - International/Other Brands
- Septanest / Septocaine / Ultracaine
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 4% Astracaine Dental With Epinephrine 1:200,000 (0.005mg/ml) Articaine hydrochloride (40 mg) + Epinephrine (0.005 mg) Solution Infiltration Dentsply Pharmaceutical 1997-02-26 2003-11-28 Canada 
4% Astracaine Dental With Epinephrine 1:200,000 (0.005mg/ml) Articaine hydrochloride (40 mg) + Epinephrine (0.005 mg) Solution Infiltration Dentsply Pharmaceutical 2004-01-29 Not applicable Canada 4% Astracaine Dental With Epinephrine Forte 1:100,000 (0.01mg/ml) Articaine hydrochloride (40 mg) + Epinephrine (0.01 mg) Solution Infiltration Dentsply Pharmaceutical 1997-02-26 2003-11-28 Canada 4% Astracaine Dental With Epinephrine Forte 1:100,000 (0.01mg/ml) Articaine hydrochloride (40 mg) + Epinephrine (0.01 mg) Solution Infiltration Dentsply Pharmaceutical 2004-01-29 Not applicable Canada Articadent Articaine hydrochloride (40 mg/1mL) + Epinephrine bitartrate (0.01 mg/1mL) Injection, solution Subcutaneous Dentsply Pharmaceutical 2000-04-03 Not applicable US 
Articadent Articaine hydrochloride (40 mg/1mL) + Epinephrine bitartrate (0.005 mg/1mL) Injection, solution Subcutaneous Dentsply Pharmaceutical 2000-04-03 Not applicable US Articaine Articaine hydrochloride (40 mg/1mL) + Epinephrine bitartrate (0.005 mg/1mL) Injection, solution Subcutaneous NDC, Inc. 2015-12-04 Not applicable US Articaine Articaine hydrochloride (40 mg/1mL) + Epinephrine bitartrate (0.005 mg/1mL) Injection, solution Subcutaneous Patterson Dental 2014-12-22 Not applicable US Articaine Articaine hydrochloride (40 mg/1mL) + Epinephrine bitartrate (0.01 mg/1mL) Injection, solution Subcutaneous Darby Dental Supply Llc 2017-03-01 2018-01-02 US Articaine Articaine hydrochloride (40 mg/1mL) + Epinephrine bitartrate (0.01 mg/1mL) Injection, solution Subcutaneous NDC, Inc. 2015-06-22 Not applicable US
Categories
- ATC Codes
- N01BB58 — Articaine, combinationsN01BB08 — Articaine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as thiophene carboxylic acids and derivatives. These are compounds containing a thiophene ring which bears a carboxylic acid group (or a salt/ester thereof).
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Thiophenes
- Sub Class
- Thiophene carboxylic acids and derivatives
- Direct Parent
- Thiophene carboxylic acids and derivatives
- Alternative Parents
- Methyl esters / Heteroaromatic compounds / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Monocarboxylic acids and derivatives / Dialkylamines / Carboximidic acids / Organopnictogen compounds / Organooxygen compounds / Organic oxides show 1 more
- Substituents
- Amine / Amino acid or derivatives / Aromatic heteromonocyclic compound / Carboximidic acid / Carboximidic acid derivative / Carboxylic acid derivative / Carboxylic acid ester / Heteroaromatic compound / Hydrocarbon derivative / Methyl ester show 12 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- D3SQ406G9X
- CAS number
- 23964-58-1
- InChI Key
- QTGIAADRBBLJGA-UHFFFAOYSA-N
- InChI
- InChI=1S/C13H20N2O3S/c1-5-6-14-9(3)12(16)15-10-8(2)7-19-11(10)13(17)18-4/h7,9,14H,5-6H2,1-4H3,(H,15,16)
- IUPAC Name
- methyl 4-methyl-3-[2-(propylamino)propanamido]thiophene-2-carboxylate
- SMILES
- CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC
References
- Synthesis Reference
U.S. Patent 3,910,924.
- General References
- Not Available
- External Links
- KEGG Drug
- D07468
- PubChem Compound
- 32170
- PubChem Substance
- 310264968
- ChemSpider
- 29837
- BindingDB
- 50225496
- 592464
- ChEBI
- 91834
- ChEMBL
- CHEMBL1093
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Articaine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Anesthesia Complications / Anesthesia Morbidity / Dental Implant Failed / Surgical Complications From Local Anesthesia 1 4 Completed Health Services Research Adverse Reaction to Other Local Anesthetics / Impacted Third Molar Tooth 1 4 Completed Other Periodontitis 1 4 Completed Prevention Anesthesia of Mucous Membrane 1 4 Completed Supportive Care Pain 1 4 Completed Treatment Dental Extraction / Maxillary Teeth / Overcoming the Failure of Anaesthesia 1 4 Completed Treatment Gastroscopy 1 4 Completed Treatment Irreversible Pulpitis 1 4 Completed Treatment Irreversible Pulpitis / Pain 1 4 Completed Treatment Local Anesthesia of the Skin 3
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Dental 72 mg Injection Submucosal Injection, solution Dental; Infiltration Solution Dental 0.006 mg/ml Solution Dental 0.012 mg/ml Injection Dental 40 mg Injection 40 mg/mL Solution Infiltration 0.009 mg Liquid Infiltration Solution Dental 0.018 mg Injection, solution Subcutaneous Injection, solution Submucosal Solution Infiltration Injection 80 mg/2mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 172-173 U.S. Patent 3,910,924. - Predicted Properties
Property Value Source Water Solubility 0.0285 mg/mL ALOGPS logP 1.93 ALOGPS logP 3.25 ChemAxon logS -4 ALOGPS pKa (Strongest Acidic) 11.61 ChemAxon pKa (Strongest Basic) 8.68 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 67.43 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 76.78 m3·mol-1 ChemAxon Polarizability 30.54 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on June 20, 2014 11:45 / Updated on June 12, 2020 11:42
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg","ThriveHealth-1.jpg":"/assets/ads/ThriveHealth-1-fe42678c71bf2ec7d508fde77efbe9f0aa868c5fa03bd39a7e1c97cefac0fa9d.jpg","ThriveHealth-2.jpg":"/assets/ads/ThriveHealth-2-32bb14bb00de8a1b2efc2a51ce37f490c01e76dac7b9c09b6b831c50640b6567.jpg","ThriveHealth-3.jpg":"/assets/ads/ThriveHealth-3-e184eae1745f8aa22525b294b761ee89f5a854a434d50e5d6d37c0b77f2cf523.jpg","ThriveHealth-4.jpg":"/assets/ads/ThriveHealth-4-218f710e6d20831711d0920e585b986217c38f38d9849b8dd32bb56f68d2eea9.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates